This content was funded by Menarini Stemline and is intended for healthcare professionals only.
Disclaimer:
NEXPOVIO®️ (selinexor) ▼ is indicated:1
In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. In combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
In these short video series, Elena Zamagni, coauthor of the EMN Research Italy publication, shares key insights on managing lenalidomide-refractory multiple myeloma patients in Italy.2 Watch to learn more about a multi-criteria decision framework designed to enhance treatment selection post-DRd.
Key topics:
- Understanding the major drivers and prioritization for the treatment of RRMM patients at first relapse.
- Impact of the results on daily clinical practice: criteria for optimal treatment selection
- Importance of achieving the right balance between efficacy, safety and global patient management.
- Therapeutic options currently EMA-approved and reimbursed in Italy for lenalidomide-refractory patients in 2L.
- Sharing of the advantages of approved regimens in patients with high unmet needs.
Speaker
Elena Zamagni
University of Bologna, Italy
The content is based on the Italian treatment landscape and access reality. This might differ in other countries. This analysis is based on subjective expert weighting and literature review, not on head-to-head trials.
References
1. EMA (2022) Nexpovio Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/nexpovio-epar-product-information _en.pdf. Last Accessed: 6 June 2025.
2. Boccadoro M et al. Supporting treatment decision-making for lenalidomide-refractory multiple myeloma patients post-DRd in Italy: a multi-criteria decision framework. PB2976. EHA, 12-15 June, 2025.
| Adverse Events Reporting: ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the Summary of Products Characteristics for how to report adverse reactions. Prescribing Information for NEXPOVIO®️ can be accessed via the following link: https://www.ema.europa.eu/en/documents/product-information/nexpovio-epar-product-information_en.pdf. See section 4.8 of the Summary of Products Characteristics for how to report adverse reactions. To Report Adverse Events: [email protected] |
